PDCD1 and B-cell chronic lymphocytic leukemia: Ibrutinib therapy continued for at least five cycles resulted in decreased expression of the inhibitory programmed cell death 1 on T cells and CD200 on B-CLL cells, which play a role in the functional CD8+ T cell response.